Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases - Wikidata - wikimedia - TriplyDB

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

http://www.wikidata.org/entity/Q36814487

about

Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications Fingolimod for the treatment of neurological diseases-state of play and future perspectives Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation Plasma sphingomyelin and longitudinal change in percent emphysema on CT. The MESA lung study Towards lipidomics of low-abundant species for exploring tumor heterogeneity guided by high-resolution mass spectrometry imaging A neurotoxic glycerophosphocholine impacts PtdIns-4, 5-bisphosphate and TORC2 signaling by altering ceramide biosynthesis in yeast Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.Characterization of acid sphingomyelinase activity in human cerebrospinal fluid Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease.The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden.White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?Peripheral sphingolipids are associated with variation in white matter microstructure in older adults.Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis.Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease.A plural role for lipids in motor neuron diseases: energy, signaling and structure.APP Function and Lipids: A Bidirectional Link.Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat.Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.Sphingolipids: membrane microdomains in brain development, function and neurological diseases.Lipidomics in translational research and the clinical significance of lipid-based biomarkers.Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease.Sphingosine-1-phosphate and its effect on glucose deprivation/glucose reload stress: from gene expression to neuronal survival Inflammation Combined with Ischemia Produces Myelin Injury and Plaque-Like Aggregates of Myelin, Amyloid-β and AβPP in Adult Rat Brain.The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.Genetic variation modifies risk for neurodegeneration based on biomarker status.A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise.Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease.Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders.Comparative atomic-scale hydration of the ceramide and phosphocholine headgroup in solution and bilayer environments

P2860

Q26740418-91926E19-C243-4184-9DB6-1B4732B3F223 Q27026175-D1FC2283-F3AF-4A45-AA2E-280DF091B019 Q28087030-CCFA70C4-3800-4F1B-971B-E331A957C940 Q28389768-69DC50FE-6641-4BB7-80B8-27A5CC055A03 Q28393497-3453E227-3A91-49E0-9CD2-1DC20A1D0370 Q28539054-7C921A2E-0A95-4CE5-96F2-BA8C5619027D Q29248109-11FB8B7B-A326-4ADF-A796-C3E3EF92C14F Q30363059-EEFB252C-50B5-46EE-A450-24BCD57B98B2 Q33902931-A48D6A57-32A5-43F7-8CF4-9D7B680B8E19 Q34712835-D98C3775-88AB-4651-8D68-0D026D7C93DE Q35915842-B98F791E-F2D6-454E-988F-43AFE9763256 Q36121819-E70360E3-8C8A-4505-BCDB-7331D95DDBDE Q36437623-CFF82570-B99C-49D8-8174-74B624AD5AA6 Q36768801-221210B8-A75D-4DD3-B04D-890C1F242365 Q36973077-74AD1059-44A6-45C0-8C4D-6B0A85B50563 Q37532200-A9AEBCC9-E936-42F2-BF5A-CEBC05A7D0DC Q37572116-D0FB13B9-A5CB-4C37-817B-FE8AFE3B6E61 Q37594297-A77C67E2-CB0E-4C6B-83E7-DFCD55093011 Q37692220-E375679B-13D1-4289-B3F1-FE6F718DE175 Q38697509-A96CC665-5116-4C09-B371-918F6D9AEF20 Q39320214-9354ED8A-9683-47ED-88AD-FDB533D75E5E Q39342245-61A878DA-144E-46D0-955D-ECA18081D76A Q39408952-3C7FB3E2-16F8-4BE7-A16C-1C9FDE49BB6E Q40444820-94BB0E2D-E5CE-4C17-B172-0B9687C995D4 Q40764980-A2D58522-135D-4B65-8B88-F578EE4614B4 Q42144566-AFBBCDDB-5336-4934-A472-672383B1061A Q43988916-23B473C1-9AF7-4DD1-B450-ADA0BCA15B85 Q46000358-92419F8B-962C-40E3-B030-A8CE16F2F3B3 Q47146081-50EE97F0-B78F-4DBE-8BEC-BB325E13DF84 Q47149447-7E38193A-404C-4F85-B37B-5D6284DEF576 Q48245644-51DEE4EC-6967-47F5-8600-4640B008D136 Q48320658-B3D1B69A-5885-433E-9D9D-9E28F31F816D Q55122433-EEDE97CF-71E4-4222-9299-F3C6BE2D738F Q56875875-369283A6-0A99-4A9D-9CA9-35D04D772920

P2860

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

http://www.wikidata.org/entity/Q36814487

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@ast

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@en

type

label

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@ast

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@en

prefLabel

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@ast

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@en

P1433

Q36814487-55D8C311-5DB8-4DBB-B500-5627F055BBBA

P1476

Q36814487-522EC16D-3708-4597-8894-8F6C549D0992

P2093

Q36814487-1362C0AE-C22B-4793-A4B1-D03443AFAE2E

Q36814487-568617D5-7156-4FD7-8910-B2BFE05C3B17

Q36814487-8D6805B9-7407-4661-ABAB-AC48B839B3F4

Q36814487-A4E9B3EB-F9F4-4A24-A8CB-615ADF2448B8

Q36814487-CEDCBFDA-8967-4BC4-A285-A2426E2E6232

Q36814487-E04BB775-D470-4763-8DD8-B2BC86705B74

Q36814487-F2C2665D-9678-44EC-97F8-617E925D577F

P2860

Q36814487-053C37C6-FE0A-4647-AB96-9E5B6E353A87

Q36814487-0DCBC256-FE0C-4C11-AEF7-5FD2614C233B

Q36814487-14713A28-3C38-4B46-83CC-CA698BFFA761

Q36814487-26AF6933-17D6-484A-B2A8-8560CE1F5E24

Q36814487-283CEF5D-7BD9-43E2-BDEB-65B8BB55BBFE

Q36814487-384217B2-BAD2-4CFC-A45F-1508CFB25CF1

Q36814487-470EF81A-5AAA-4D1F-AC7D-D81F47A0EDE3

Q36814487-51A4C698-F498-4346-B47A-0F0C98902A7F

Q36814487-69D04069-4488-40ED-8662-7E83CAE07761

Q36814487-76B8A5A5-39BD-4B59-AC4A-6D73477380B8

P304

Q36814487-E84C953C-F86F-47B7-818C-53296A192A00

P31

Q36814487-72021B57-7765-486C-83BD-90088B296444

P356

Q36814487-6E7D66B9-1403-413F-863A-A29C02D8BEE4

P433

Q36814487-79A26C87-EF5E-469B-B970-F1AAF545F85B

P478

Q36814487-EE2B5F12-A2A4-4ED3-9CE1-F599BAB209AE

P50

Q36814487-552519D5-E4DF-4BFA-8EA0-5EDA0EF0D479

P577

Q36814487-618D29D5-7285-42AE-9B7C-47D5B9C11280

P698

Q36814487-8E9A9C5B-4B30-45BC-A375-E4094467F92F

P921

Q36814487-18A86238-0CDF-4557-AA15-48F14FE3CB96

Q36814487-F6F030E8-9D78-477C-996B-C7512215AC63

P932

Q36814487-086C5C87-C63B-4D6C-AC52-AAC8EA429951

P356

JAD-2011-111202

P1433

Journal of Alzheimer's Disease

P1476

Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases

@en

P2093

Jun Yang

http://www.w3.org/2001/XMLSchema#string

Kangling Zhang

http://www.w3.org/2001/XMLSchema#string

Minwoo Andrew Song

http://www.w3.org/2001/XMLSchema#string

Penelope J Duerksen-Hughes

http://www.w3.org/2001/XMLSchema#string

Spencer Tung

http://www.w3.org/2001/XMLSchema#string

Valery Filippov

http://www.w3.org/2001/XMLSchema#string

Wolff M Kirsch

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase

Evidence for a membrane defect in Alzheimer disease brain

Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas.

Deregulation of sphingolipid metabolism in Alzheimer's disease.

Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry.

Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth.

High activity of acid sphingomyelinase in major depression.

Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate.

Ceramide in apoptosis: an overview and current perspectives.

Sphingolipid metabolism in neural cells.

P304

537-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2011-111202

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Harry V Vinters

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22258513

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

neurodegeneration

P932

3643694

http://www.w3.org/2001/XMLSchema#string